2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1724

Disease Manifestations and Impact on Quality of Life in Subjects with Pre-Pubertal Onset Systemic Lupus Erythematosus
Abstract Number: 1725

Disease Activity in Childhood-Onset Systemic Lupus Erythematosus: Initial Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 1726

Disease Activity and Health Care Utilization Among Young Adults with Childhood-onset Lupus Transitioning to Adult Care: Follow-Up Data from the Pediatric Lupus Outcomes Study
Abstract Number: 1727

Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care
Abstract Number: 1728

Persistent Disease Activity Is Associated with Avascular Necrosis Development in Juvenile Systemic Lupus Erythematosus
Abstract Number: 1729

Infections and Mortality in 230 Childhood Lupus Patients: A Single Center Experience from North India
Abstract Number: 1730

Impact of Preceding and Co-existing Autoimmune Cytopenias on Severity of Childhood-onset Systemic Lupus Erythematosus: A Single-Center Retrospective Cohort Study
Abstract Number: 1731

Validation of the 2017 Weighted Criteria in Pediatric Systemic Lupus Erythematosus (SLE)
Abstract Number: 1732

Evaluating the New 2018 ACR/EULAR SLE Classification in Pediatric Patients
Abstract Number: 1733

Long-term Renal Survival of Pediatric Onset Lupus Patients in a Population-Based Cohort
Abstract Number: 1734

Low Bone Mineral Density Was Associated with Lupus Nephritis Irrespective of Duration on Steroid Treatment in a Large Observational Study of Juvenile Systemic Lupus Erythematosus Patients
Abstract Number: 1735

Clinical Variables Influencing Prednisone Dosing Towards the Development of Corticosteroid Treatment Algorithms in Pediatric Proliferative Lupus Nephritis
Abstract Number: 1736

Cognitive Impairment in Childhood-Onset Systemic Lupus Erythematosus: Early Detection with MRI Spectroscopy and Its Association with MOG Antibodies
Abstract Number: 1737

Systemic Vascular Involvement in Kawasaki Disease: A Single Center Cohort
Abstract Number: 1738

Tracking Whole-Brain Volumetric Trends in Childhood-onset Systemic Lupus Erythematosus Patients in the Clinical Setting by Magnetic Resonance Imaging

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].